CING Company Profile and Key Details

Cingulate Inc. (NASDAQ:CING) closed at $5.02 USD, losing -$0.15 (-2.90%) from the previous close of $5.17. The stock is currently mid-range between its 52-week high and low $3.16 and $11.89. With a market capitalization of about $67.61 million, Cingulate Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.89). Key stats such as the average daily volume over the past year has been around 218.93 thousand shares, volume is running light vs its 52-week average. Headquartered in Kansas City, KS, Cingulate Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shane J. Schaffer, the company employs approximately 14 people and listed since December 08, 2021. Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD).

Cingulate Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.40. This means the shares are trading above this model’s fair value.

Cingulate Inc. has 14.54 million shares outstanding. The public float is 14.21 million shares, elevated short interest at 10.12% of float. This equals 1.06 million shares. The short ratio is 6.78 days. Institutional investors hold 12.86% of the float. Insiders own 30.54%. GIVENS GREGG WM holds 154.32 thousand shares, Hargroves Thomas Jeffrey has 77.82 thousand shares and Werth Peter J. has 15.56 thousand shares.

CING has shown sold momentum, gaining 21.15% over the past week and 59.46% over the past quarter, though year-to-date performance is up 35.94%. Short-term trend indicators are bearishly aligned (SMA20 2.37%, SMA50 20.92%, SMA200 47.08%). The stock’s 14-day RSI is 56.19 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.06% below its high and over 102.81% above its low. Average 10-day trading volume of 91.23 thousand shares is below the 3-month average of 217.37 thousand, indicating normal recent market interest.

Cingulate Inc. generated EPS of -$5.29 over the past year. Five-year average earnings growth is 40.0%. Wall Street analysts project EPS growth of 60.26% annually over the next five years. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.63. Next year's EPS is expected at $51.52. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $9.00. The high target offers 1135.06% upside. The low target suggests 79.28% downside. The mean target is $30.62. This offers 509.96% upside. Cingulate Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by -28.57%. The prior quarter beat by 79.25%. Over the last six quarters, Apple has recorded several small beats. These include 4.0% in May 08, 2025.

Cingulate Inc. trades at a P/E ratio of -1.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.17 suggesting the stock is closer to book value. The P/FCF stands at -3.25, also below market averages.

Cingulate Inc. (NASDAQ:CING) shares are up 35.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cingulate Inc. trading at a premium to the broader market with a P/E of -1.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.88, suggesting 375.7% upside. Our AI forecast model points to short-term weakness (-4.38% over two weeks), a medium-term fall (-35.66% over three months), and a longer-term gain (51.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cingulate Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.38%, with price expected at $4.80 by September 25, 2026, within a range of $4.63 to $5.00 3-Month Outlook: Projected fall of -35.66%, reaching $3.23 by December 10, 2026, with a range of $2.79 to $3.52. 1-Year Outlook: Projected gain of 51.2%, with price at $7.59 by September 10, 2027, within a range of $3.82 to $8.93.